The McLean, Virginia-based firm reported $181 million in earnings, while revenue of $2.78 billion fell below analyst expectations, according to company officials.
On Friday, Dr. Reddy's Laboratories reported fiscal second-quarter profit of $97 million, surpassing analyst expectations as strong domestic demand cushioned weakness in its key United States market.
Declining sales of Lenalidomide, a generic cancer drug, drove the slowdown as North America generic business revenue fell to $264 million amid increased competition and pricing pressure.
India business revenue rose 17.2% to 18.5 billion rupees, providing a bright spot domestically. The company expects to resume generic semaglutide supplies to global markets by November 2026 after resolving production quality issues.
The company's CDMO business generated over $100 million in revenue over the last 12 months, bolstered by filing 28 Drug Master Files globally during the second quarter.
CEO Erez Israeli expects the CDMO business to grow two-fold to three-fold over the next three to four years, as the company awaits a regulatory decision for its abatacept biosimilar with a PDUFA goal date of December 22, 2026.